Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5493)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
May 20, 2021 (publication date) through Apr 27, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Methodology
ISSN
2222-0682
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Petrelli F, Cherri S, Ghidini M, Perego G, Ghidini A, Zaniboni A. Tocilizumab as treatment for COVID-19: A systematic review and meta-analysis. World J Methodol 2021; 11(3): 95-109 [PMID: 34026583 DOI: 10.5662/wjm.v11.i3.95] |
|---|---|
| URL: | https://www.wjgnet.com/2222-0682/full/v11/i3/95.htm |
| Number | Citing Articles |
| 1 |
Amanda M. Burkhardt, Angela Lu, Isaac Asante, Stan Louie. Coronavirus Disease 2019 (COVID‐19). 2023; : 290 doi: 10.1002/9781119789741.ch13
|
| 2 |
Mohammad Mahdi Rezaei Tolzali, Maryam Noori, Pourya Shokri, Shayan Rahmani, Shokoufeh Khanzadeh, Seyed Aria Nejadghaderi, Asra Fazlollahi, Mark J. M. Sullman, Kuljit Singh, Ali‐Asghar Kolahi, Shahnam Arshi, Saeid Safiri. Efficacy of tocilizumab in the treatment of COVID‐19: An umbrella review. Reviews in Medical Virology 2022; 32(6) doi: 10.1002/rmv.2388
|
| 3 |
Elham Assareh, Mohammad Amin Abbasi, Mahsa Heidari, S. Mohsen Asghari. A Review on COVID-19: Primary Receptor, Endothelial Dysfunction, Related Comorbidities, and Therapeutics. Iranian Journal of Science 2023; 47(1): 1 doi: 10.1007/s40995-022-01400-8
|
| 4 |
Wiktor Schmidt, Katarzyna Pawlak-Buś, Barbara Jóźwiak, Piotr Leszczyński. Identification of Clinical Response Predictors of Tocilizumab Treatment in Patients with Severe COVID-19 Based on Single-Center Experience. Journal of Clinical Medicine 2023; 12(6): 2429 doi: 10.3390/jcm12062429
|
| 5 |
Brent J. Tschirhart, Xiangru Lu, Aristide Laurel Mokale Kognou, Claudio M. Martin, Marat Slessarev, Douglas D. Fraser, Aleksandra Leligdowicz, Bradley Urquhart, Qingping Feng. Pharmacokinetics of recombinant human annexin A5 (SY-005) in patients with severe COVID-19. Frontiers in Pharmacology 2024; 14 doi: 10.3389/fphar.2023.1299613
|
| 6 |
Diana Dueñas, Jorge Daza, Yamil Liscano. Coinfections and Superinfections Associated with COVID-19 in Colombia: A Narrative Review. Medicina 2023; 59(7): 1336 doi: 10.3390/medicina59071336
|